IL320603A - Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer - Google Patents
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancerInfo
- Publication number
- IL320603A IL320603A IL320603A IL32060325A IL320603A IL 320603 A IL320603 A IL 320603A IL 320603 A IL320603 A IL 320603A IL 32060325 A IL32060325 A IL 32060325A IL 320603 A IL320603 A IL 320603A
- Authority
- IL
- Israel
- Prior art keywords
- avb6
- antibodies
- antibody
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263422098P | 2022-11-03 | 2022-11-03 | |
| US202363457205P | 2023-04-05 | 2023-04-05 | |
| PCT/US2023/078437 WO2024097816A1 (en) | 2022-11-03 | 2023-11-02 | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320603A true IL320603A (en) | 2025-07-01 |
Family
ID=89073045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320603A IL320603A (en) | 2022-11-03 | 2025-04-30 | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4611819A1 (en) |
| JP (1) | JP2025537099A (en) |
| KR (1) | KR20250089558A (en) |
| CN (1) | CN120435319A (en) |
| AU (1) | AU2023372538A1 (en) |
| IL (1) | IL320603A (en) |
| MX (1) | MX2025005210A (en) |
| TW (1) | TW202434303A (en) |
| WO (1) | WO2024097816A1 (en) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3668186D1 (en) | 1985-04-01 | 1990-02-15 | Celltech Ltd | TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| FI102355B1 (en) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Process for Preparation of Anthracycline Immunoconjugates with a Linking Link |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| ATE120454T1 (en) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | COUPLING AGENT AND STERICALLY HINDERED CONJUGATES THEREOF BOUND WITH DISULFIDE. |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| JP3583420B2 (en) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | Targeted immunization with bispecific reagents |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| ATE255131T1 (en) | 1991-06-14 | 2003-12-15 | Genentech Inc | HUMANIZED HEREGULIN ANTIBODIES |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| DE60045319D1 (en) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Method and apparatus for retrieving texture images |
| ES2544527T3 (en) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| GEP20115195B (en) | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| JP5171621B2 (en) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | Monomethylvaline compound having phenylalanine side chain modification at C-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| DK2099823T4 (en) | 2006-12-01 | 2022-05-09 | Seagen Inc | Target binding agent variants and uses thereof |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| US10613092B2 (en) | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
| IL293195A (en) | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
| JP2023548538A (en) * | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | combination therapy |
-
2023
- 2023-11-02 AU AU2023372538A patent/AU2023372538A1/en active Pending
- 2023-11-02 JP JP2025523823A patent/JP2025537099A/en active Pending
- 2023-11-02 CN CN202380090017.8A patent/CN120435319A/en active Pending
- 2023-11-02 WO PCT/US2023/078437 patent/WO2024097816A1/en not_active Ceased
- 2023-11-02 TW TW112142158A patent/TW202434303A/en unknown
- 2023-11-02 KR KR1020257018398A patent/KR20250089558A/en active Pending
- 2023-11-02 EP EP23817632.5A patent/EP4611819A1/en active Pending
-
2025
- 2025-04-30 IL IL320603A patent/IL320603A/en unknown
- 2025-05-02 MX MX2025005210A patent/MX2025005210A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024097816A1 (en) | 2024-05-10 |
| JP2025537099A (en) | 2025-11-14 |
| CN120435319A (en) | 2025-08-05 |
| KR20250089558A (en) | 2025-06-18 |
| EP4611819A1 (en) | 2025-09-10 |
| TW202434303A (en) | 2024-09-01 |
| MX2025005210A (en) | 2025-06-02 |
| AU2023372538A1 (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299334A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL276768A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL280617A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL304168A (en) | B7h4-targeted antibody-drug conjugates and methods of use thereof | |
| IL307201A (en) | Triazine derivatives and their use in the treatment of cancer. | |
| IL274122A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
| IL314346A (en) | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer | |
| IL314828A (en) | Antibody-drug conjugates and their uses | |
| IL320894A (en) | Ceacam5 antibody-drug conjugates and methods of use thereof | |
| IL278988A (en) | Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer | |
| IL317101A (en) | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof | |
| IL308508A (en) | Use of her2-targeting antibody-drug conjugate in treatment of her2-low expressing breast cancer | |
| IL319484A (en) | Antibody-drug conjugates targeting napi2b and methods of use | |
| IL309249A (en) | Conjugates comprising phosphoantigens and their use in therapy | |
| EP4486344A4 (en) | Oral pclx-001 in the treatment of human cancer | |
| IL308486A (en) | Use of antibody-drug conjugate in combination with immune checkpoint inhibitor in treatment of urothelial cancer | |
| PL4217007T3 (en) | Peptidic conjugates of sn38 useful in the treatment of cancer | |
| EP4228710A4 (en) | Therapeutic radiolabelled conjugates and their use in therapy | |
| CA3272322A1 (en) | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer | |
| IL327342A (en) | Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer | |
| IL319205A (en) | Tissue factor antibody-drug conjugates and uses thereof | |
| IL316020A (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| HK40085049A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| HK40045679A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |